



ASX Announcement

For immediate release

16 May 2019

CSL Names Paul McKenzie as Chief Operating Officer

CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today named Dr. Paul McKenzie, an accomplished global leader with diverse biotechnology experience, as Chief Operating Officer (COO), effective 3 June.

“Paul has a demonstrated track record of success in leading operational excellence and he brings significant leadership capabilities that will continue to drive CSL’s sustainable growth,” said CSL CEO & Managing Director Mr. Paul Perreault. “Throughout his 30-year career, Paul has earned a reputation as a patient-focused business leader -- an important attribute as we continue to invest in our science, facilities and commercial capabilities for delivering better outcomes to patients and protecting public health. I look forward to working with Paul and the rest of our leadership team in executing our strategy and continuing to sustainably grow our global business.”

Dr. McKenzie, 53, has served in a range of progressive operational leadership roles in the biopharma and biotech industries since 1992. Most recently, he was Executive Vice President of Pharmaceutical Operations & Technology at Biogen where he was accountable for asset management, technical development, global manufacturing, supply chain operations, CMC regulatory, quality and engineering. Dr. McKenzie also held leadership roles in research & development, science & technology and operations with Johnson & Johnson, Bristol-Myers Squibb and Merck earlier in his career.

He earned his Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and was awarded his Ph.D. in Chemical Engineering from Carnegie Mellon University. Dr. McKenzie is an accomplished author and thought leader on operational excellence in the biotech industry.

At CSL, Paul will be accountable for leading the newly formed global end-to-end supply chain organisation and its accompanying strategy. This includes manufacturing, manufacturing technical support, CSL Plasma, quality, engineering, environment, health & safety (EHS), business technology, planning, logistics, sourcing, business services and enterprise excellence.

“Now is an incredibly exciting time to be a part of CSL. I am thrilled to join a growing global biotech leader and a well-established management team that is keenly focused on creating value for shareholders, patients, employees and the communities in which it operates,” Dr. McKenzie said. “I look forward to contributing to CSL’s future growth and success in delivering on the promise of innovative medicines to treat patients and protect public health around the world.”



ASX Announcement

Page 2

16 May 2019

About CSL

CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 60 countries and employs 22,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visit www.csl.com

For further information, please contact:

Investors:

Mark Dehring
Head of Investor Relations
Phone: +61 393 893 407
Email: Mark.Dehring@csl.com.au

Media:

Jemimah Brennan
Head of APAC Corporate Communications
Phone: +61 412 635 483
Email: Jemimah.Brennan@csl.com.au